IT1149328B - Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso - Google Patents

Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso

Info

Publication number
IT1149328B
IT1149328B IT48908/82A IT4890882A IT1149328B IT 1149328 B IT1149328 B IT 1149328B IT 48908/82 A IT48908/82 A IT 48908/82A IT 4890882 A IT4890882 A IT 4890882A IT 1149328 B IT1149328 B IT 1149328B
Authority
IT
Italy
Prior art keywords
absorbed
compounds
pharmaceutical composition
oral administration
large intestine
Prior art date
Application number
IT48908/82A
Other languages
English (en)
Other versions
IT8248908A0 (it
Inventor
John Rhodes
Brin Kenneth Evans
Original Assignee
Tillott J B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10523624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1149328(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillott J B Ltd filed Critical Tillott J B Ltd
Publication of IT8248908A0 publication Critical patent/IT8248908A0/it
Application granted granted Critical
Publication of IT1149328B publication Critical patent/IT1149328B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IT48908/82A 1981-07-31 1982-07-29 Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso IT1149328B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8123573 1981-07-31

Publications (2)

Publication Number Publication Date
IT8248908A0 IT8248908A0 (it) 1982-07-29
IT1149328B true IT1149328B (it) 1986-12-03

Family

ID=10523624

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48908/82A IT1149328B (it) 1981-07-31 1982-07-29 Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso

Country Status (14)

Country Link
US (2) US5541170A (it)
EP (1) EP0097651B1 (it)
JP (1) JPS58501174A (it)
AT (1) ATE17189T1 (it)
AU (1) AU551173B2 (it)
CA (1) CA1172570A (it)
DE (1) DE3268277D1 (it)
DK (1) DK158931C (it)
FI (1) FI85216C (it)
GB (1) GB2123695B (it)
IT (1) IT1149328B (it)
NO (1) NO159696C (it)
WO (1) WO1983000435A1 (it)
ZA (1) ZA825384B (it)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (it) * 1980-03-20 1982-03-11
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
GB2196252B (en) * 1986-09-18 1990-10-17 London Pharmacy Innovation Gastric controlled-release dosage forms
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JPH01299226A (ja) * 1988-05-27 1989-12-04 Seikagaku Kogyo Co Ltd サラゾスルファピリジン腸溶顆粒
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
AU654483B2 (en) * 1990-04-18 1994-11-10 University Of Utah Research Foundation Crosslinked hydrogels containing azobonds
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
NL9002336A (nl) * 1990-10-24 1992-05-18 Leuven K U Res & Dev Bekledings- of matrixmateriaal voor geneesmiddelen.
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
AU1587392A (en) * 1991-03-15 1992-10-21 Norwich Eaton Pharmaceuticals, Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
US5654004A (en) * 1992-11-06 1997-08-05 Hisamitsu Pharmaceutical Co., Inc. Oral pharmaceutical preparation releasable in the lower digestive tract
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
SE9401738D0 (sv) * 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
WO1997038969A1 (fr) * 1996-04-12 1997-10-23 Japan Atomic Energy Research Institute POLYMERES SENSIBLES AU pH
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
WO2000006128A1 (fr) 1998-07-28 2000-02-10 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
CA2344306A1 (en) * 1998-09-21 2000-03-30 Amato Pharmaceutical Products, Ltd. Oral drug delivery system for enhancing the bioavailability of active form of glycyrrhizin
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
CA2360655C (en) 1999-01-29 2007-03-20 Losan Pharma Gmbh Pharmaceutical compositions
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
CA2373940A1 (en) 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20030114349A1 (en) * 2000-04-27 2003-06-19 The Procter & Gamble Company Coating composition for solid bodies
EP2263654B1 (en) 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Compositions for improving the oral absorption of antimicrobial agents
TWI249519B (en) 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
AR036797A1 (es) * 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US20060275253A1 (en) 2003-09-01 2006-12-07 Kazunari Ushida Beta hydroxy short to medium chain fatty acid polymer
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
BRPI0514827A (pt) * 2004-09-01 2008-06-24 Procter & Gamble composições compreendendo ácido 5-amino-2hidróxi- benzóico e açúcar redutor
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN103948609A (zh) * 2005-08-24 2014-07-30 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CN101489986A (zh) * 2006-06-06 2009-07-22 安泰碧治疗公司 曲美布汀和n-去甲基曲美布汀的盐
AU2006348138A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis using aminosalicylate
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
US20100136125A1 (en) * 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
MX2011003595A (es) * 2008-10-03 2011-07-28 Falk Pharma Gmbh Composiciones y metodos para el tratamiento de enfermedades intestinales con mesalamina granulada.
US8729097B2 (en) 2008-10-06 2014-05-20 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CN109172816A (zh) 2012-03-29 2019-01-11 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014152450A1 (en) 2013-03-15 2014-09-25 Warner Chilcott Company, Llc Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
USD809116S1 (en) 2015-11-02 2018-01-30 Pura Scents Dispenser
US9827343B2 (en) 2015-11-02 2017-11-28 Pura Scents, Inc. Scent dispensation and fluid level sensing
USD816506S1 (en) 2015-11-02 2018-05-01 Pura Scents, Inc. Vial for a scent dispenser
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US20230203477A1 (en) 2020-05-26 2023-06-29 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
PH10958A (en) * 1967-08-18 1977-10-13 Abbott Lab Tablet preparation
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition
US4190716A (en) * 1978-12-20 1980-02-26 Dynapol Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
JPS57500432A (it) * 1980-03-20 1982-03-11
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap

Also Published As

Publication number Publication date
EP0097651A1 (en) 1984-01-11
DK128283A (da) 1983-03-21
FI85216C (fi) 1992-03-25
AU8732482A (en) 1983-02-22
US5541171A (en) 1996-07-30
NO159696C (no) 1989-02-01
DK158931B (da) 1990-08-06
ATE17189T1 (de) 1986-01-15
IT8248908A0 (it) 1982-07-29
DK128283D0 (da) 1983-03-21
JPS58501174A (ja) 1983-07-21
CA1172570A (en) 1984-08-14
DK158931C (da) 1990-12-31
US5541170A (en) 1996-07-30
EP0097651B1 (en) 1986-01-02
FI85216B (fi) 1991-12-13
GB2123695A (en) 1984-02-08
NO830948L (no) 1983-03-17
WO1983000435A1 (en) 1983-02-17
GB8322387D0 (en) 1983-09-21
FI833099A (fi) 1983-08-31
DE3268277D1 (en) 1986-02-13
AU551173B2 (en) 1986-04-17
GB2123695B (en) 1985-05-01
FI833099A0 (fi) 1983-08-31
ZA825384B (en) 1983-05-25
JPH0414083B2 (it) 1992-03-11
NO159696B (no) 1988-10-24

Similar Documents

Publication Publication Date Title
IT1149328B (it) Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso
DK516481A (da) Farmaceutisk doseringsform
FI933680A0 (fi) Orala doseringsformer foerdroejd frigoering foer behandling av tarmstoerningar
PT825858E (pt) Capsulas de libertacao dependente do tempo contendo acidos poliinsaturados omega-3 para o tratamento da doenca inflamatoria do intestino
DK0843558T3 (da) Sammensætning til forstærket optagelse af polære lægemidler fra colon
Isaacs et al. Pancreatitis after rectal administration of 5-aminosalicylic acid
Goebell et al. Oroileal transit of slow release 5-aminosalicylic acid.
ATE205705T1 (de) Arzneimittel zum wirkstoff - targetting in den dickdarm
ATE280572T1 (de) Verabreichung von arzneistoffen im unteren verdauungstrakt
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
BE901073A (fr) Composition antidiuretique a usage oral.
KR850700212A (ko) 서방성 약제학적 캼셀제
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
NL8400911A (nl) Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
TH61079A (th) ยาเม็ดเคลือบฟิล์มสำหรับความปลอดภัยที่ดีขึ้นสำหรับทางเดินกระเพาะลำไส้ตอนบน
TH31107B (th) ยาเม็ดเคลือบฟิล์มสำหรับความปลอดภัยที่ดีขึ้นสำหรับทางเดินกระเพาะลำไส้ตอนบน

Legal Events

Date Code Title Description
ITCP Complementary protection certificate

Free format text: CCP 265

MEDD Supplementary protection certificate for pharmaceutical products: granted

Free format text: CCP 265, 19920511; GIULIANI S.P.A.

TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970919